We review individual medicines or smaller groups of medicines, within medical areas where we judge there to be reason to question whether the medicine is cost-effective or not. The balance between medicines’ cost-effectiveness ratio changes over time, for example when new medicines are subsidized or when we accept new pricing for a medicine.
Prior to commencing a new review, we make prioritization analyses where we, among other things, consider sales volumes, reimbursement costs, cost per DDD, expanded indications and expired patents. We also hold a dialogue with the county councils and provide them with an opportunity to submit suggestions on which products we should review.
We may also start a review in connection with evaluating an application for a new medicine to be part of the reimbursement system. Such a review can take place if there are deficiencies within a specific medical area when it comes to usage or cost-effectiveness.
If a review is started the company or companies are informed by us.